title: Addition of low dose total body irradiation to fludarabine melphalan reduced intensity conditioning is feasible, tolerable, and may improve outcomes in patients with high-risk acute myeloid leukaemia and other high risk myeloid malignancies.
authors: Haematology Department, Royal North Shore Hospital, Sydney, New South Wales, Australia.
authors: Grace
authors: G
authors: Gifford
authors: Kelly
authors: K
authors: Wong
authors: Ian
authors: I
authors: Kerridge
authors: William
authors: W
authors: Stevenson
authors: Chris
authors: C
authors: Arthur
authors: Keith
authors: K
authors: Fay
authors: Matthew
authors: M
authors: Greenwood
mesh_terms: D000368:Aged; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D019337:Hematologic Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use*; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000627:therapeutic use; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods*; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014916:Whole-Body Irradiation / Q000379:methods*
chemical_list: D019653:Myeloablative Agonists; D014740:Vidarabine; C024352:fludarabine; D008558:Melphalan